Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)

This study — called REVIVE — is testing a combination of two powerful immunotherapy drugs (teclistamab and daratumumab) in people with high-risk smoldering multiple myeloma, which is a pre-cancer blood condition that has a high chance of progressing to full-blown myeloma. The goal is to treat it early and potentially prevent or delay it from becoming active cancer. **You may be eligible if...** - You have been diagnosed with smoldering multiple myeloma (a precancerous plasma cell condition not yet causing organ damage) - Your disease is classified as high-risk based on specific blood, urine, or bone marrow tests - You have not yet been treated with systemic therapy for this condition - Your blood counts, kidneys, calcium, and bone findings meet specific thresholds **You may NOT be eligible if...** - Your myeloma has already caused organ damage (anemia, kidney failure, high calcium, or bone lesions from the cancer) indicating active myeloma - You have already started treatment for myeloma - Your condition doesn't meet the measurable disease criteria required for this study Talk to your doctor to see if this trial is right for you.